Cargando…

A Possible Exquisite Crosstalk of Urate Transporter 1 With Other Urate Transporters for Chronic Kidney Disease and Cardiovascular Disease Induced by Dotinurad

Detalles Bibliográficos
Autores principales:	Yanai, Hidekatsu, Adachi, Hiroki, Hakoshima, Mariko, Katsuyama, Hisayuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116931/ https://www.ncbi.nlm.nih.gov/pubmed/37091888 http://dx.doi.org/10.14740/cr1496

Ejemplares similares

Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Glucose-Lowering Effects of Imeglimin and Its Possible Beneficial Effects on Diabetic Complications
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Glucagon-Like Peptide 1 Receptor Agonists Versus Sodium-Glucose Cotransporter 2 Inhibitors for Atherosclerotic Cardiovascular Disease in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

Significance of Endothelial Dysfunction Amelioration for Sodium–Glucose Cotransporter 2 Inhibitor-Induced Improvements in Heart Failure and Chronic Kidney Disease in Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Significant Effect of Oral Semaglutide on Cardiovascular Risk Factors in Patients With Type 2 Diabetes
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

The Possible Mechanisms for Improvement of Liver Function due to Sodium-Glucose Cotransporter-2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

An Effective Insulin Therapy in Combination With Sodium-Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments
por: Yanai, Hidekatsu, et al.
Publicado: (2023)

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Clinical, Biochemical, Hematological, Endocrinological and Immunological Differences Between Graves’ Disease Patients With and Without Thyroid Storm
por: Yanai, Hidekatsu, et al.
Publicado: (2019)

Clinical, Hematological, Biochemical and Radiological Characteristics for Patients With Splenic Infarction: Case Series With Literature Review
por: Hakoshima, Mariko, et al.
Publicado: (2023)

Urate transport capacity of glucose transporter 9 and urate transporter 1 in cartilage chondrocytes
por: Zhang, Bingqing, et al.
Publicado: (2019)

URAT1 is expressed in cardiomyocytes and dotinurad attenuates the development of diet-induced metabolic heart disease
por: Tanaka, Yoshiro, et al.
Publicado: (2023)

Hypouricemia and Urate Transporters
por: Otani, Naoyuki, et al.
Publicado: (2022)

A clinical pharmacology study of the novel, selective urate reabsorption inhibitor dotinurad in outpatients
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Renoprotective Effect of Xanthine Oxidase Inhibitor, Topiroxostat
por: Katsuyama, Hisayuki, et al.
Publicado: (2019)

A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients
por: Yanai, Hidekatsu, et al.
Publicado: (2021)

Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study
por: Yanai, Hidekatsu, et al.
Publicado: (2022)

Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2023)

Modulation of Urate Transport by Drugs
por: Tátrai, Péter, et al.
Publicado: (2021)

Mechanism of high affinity inhibition of the human urate transporter URAT1
por: Tan, Philip K., et al.
Publicado: (2016)

Habitual Hot-Tub Bathing and Cardiovascular Risk Factors in Patients With Type 2 Diabetes Mellitus: A Cross-Sectional Study
por: Katsuyama, Hisayuki, et al.
Publicado: (2022)

Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia
por: Kuriyama, Satoru
Publicado: (2019)

Inhibitory effect of Citrus flavonoids on the in vitro transport activity of human urate transporter 1 (URAT1/SLC22A12), a renal re-absorber of urate
por: Toyoda, Yu, et al.
Publicado: (2020)

Ependymal cells of the mouse brain express urate transporter 1 (URAT1)
por: Tomioka, Naoko H, et al.
Publicado: (2013)

Loss of the Kidney Urate Transporter, Urat1, Leads to Disrupted Redox Homeostasis in Mice
por: Jamshidi, Neema, et al.
Publicado: (2023)

An Improvement of Cardiovascular Risk Factors by Omega-3 Polyunsaturated Fatty Acids
por: Yanai, Hidekatsu, et al.
Publicado: (2018)

Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment
por: Kumagai, Yuji, et al.
Publicado: (2019)

Variation of Urate Transport in the Nephrons in Subtypes of Hyperuricemia
por: Nakamura, Toru, et al.
Publicado: (2013)

Effects of mild and moderate renal dysfunction on pharmacokinetics, pharmacodynamics, and safety of dotinurad: a novel selective urate reabsorption inhibitor
por: Fukase, Hiroyuki, et al.
Publicado: (2019)

Urate transport function of rat sodium‐dependent nucleobase transporter 1
por: Yasujima, Tomoya, et al.
Publicado: (2018)

Glucose, Fructose, and Urate Transporters in the Choroid Plexus Epithelium
por: Chiba, Yoichi, et al.
Publicado: (2020)

Urate Transporters in the Kidney: What Clinicians Need to Know
por: Chung, Sungjin, et al.
Publicado: (2021)

The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
por: Hishe, Hailemichael Z., et al.
Publicado: (2022)

A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout
por: Hosoya, Tatsuo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4qbngkvd891ot6sd5stuit7l54